Publications

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

01-12-2012

Bioanalysis

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

01-11-2012

The AAPS journal

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

01-09-2012

Investigational new drugs

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

01-08-2012

British journal of clinical pharmacology

Model-based treatment optimization of a novel VEGFR inhibitor.

01-08-2012

Journal of palliative care

Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.

16-05-2012

Cancer

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

01-05-2012

Journal of clinical pharmacology

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

01-03-2012

Journal of clinical pharmacology

Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor.

01-02-2012

Drug metabolism and disposition: the biological fate of chemicals

Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.

01-02-2012

Cancer chemotherapy and pharmacology

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.

01-01-2012

International journal of pharmaceutics

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

28-11-2011

Lung cancer (Amsterdam, Netherlands)

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

01-11-2011

Journal of analytical toxicology

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

01-10-2011

Clinical pharmacology and therapeutics

Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.

01-07-2011

The AAPS journal

Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

01-06-2011

Human antibodies

CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.

12-05-2011

Human antibodies

The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.

12-05-2011

Human antibodies

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

12-05-2011

Current clinical pharmacology

Pharmacodynamic biomarkers in model-based drug development in oncology.

01-02-2011

Computer methods and programs in biomedicine

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

01-01-2011

Clinical pharmacokinetics

Clinical pharmacokinetics of therapeutic monoclonal antibodies.

01-08-2010

Journal of pharmacokinetics and pharmacodynamics

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

01-08-2010

British journal of pharmacology

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

01-07-2010

Human antibodies

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

18-06-2010

British journal of clinical pharmacology

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

01-05-2010

Investigational new drugs

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.

01-02-2010

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-11-2009

The oncologist

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

01-09-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.

15-06-2009

Cancer chemotherapy and pharmacology

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

01-06-2009

Investigational new drugs

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.

01-04-2009

Acta oncologica (Stockholm, Sweden)

Persistent neuropathy after treatment with cisplatin and oxaliplatin.

25-03-2009

Cancer chemotherapy and pharmacology

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.

01-02-2009

Journal of pharmacokinetics and pharmacodynamics

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

01-02-2009

Cancer biotherapy & radiopharmaceuticals

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

01-02-2009

Therapeutic drug monitoring

Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.

01-02-2009

Cancer treatment reviews

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

01-02-2009

Cancer chemotherapy and pharmacology

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.

01-01-2009

British journal of clinical pharmacology

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

01-01-2009

Clinical drug investigation

Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.

11-12-2008

Pharmacogenetics and genomics

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.

01-11-2008

British journal of clinical pharmacology

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

01-10-2008

BMC clinical pharmacology

Long-term platinum retention after treatment with cisplatin and oxaliplatin.

17-09-2008

Antimicrobial agents and chemotherapy

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

01-08-2008

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

10-07-2008

Anti-cancer drugs

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.

01-07-2008

Clinical pharmacology and therapeutics

PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.

01-06-2008

Pharmacogenetics and genomics

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

01-06-2008

British journal of cancer

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

22-04-2008